This is a summary of the European public assessment report (EPAR) for Bridion. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Bridion.
Therapeutic Indication
### Therapeutic indication Reversal of neuromuscular blockade induced by rocuronium or vecuronium. For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.
Therapeutic Area (MeSH)
N/AATC Code
V03AB35
ATC Item
sugammadex
Pharmacotherapeutic Group
All other therapeutic products
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| sugammadex | N/A | 舒更葡糖钠 |
EMA Name
Bridion
Medicine Name
Bridion
Aliases
N/ANo risk management plan link.
